Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $13.76 USD
Change Today +0.25 / 1.85%
Volume 202.2K
SPNC On Other Exchanges
As of 5:10 PM 11/27/15 All times are local (Market data is delayed by at least 15 minutes).

spectranetics corp (SPNC) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/18/15 - $37.04
52 Week Low
10/14/15 - $10.65
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SPECTRANETICS CORP (SPNC)

Related News

No related news articles were found.

spectranetics corp (SPNC) Related Businessweek News

No Related Businessweek News Found

spectranetics corp (SPNC) Details

The Spectranetics Corporation, together with its subsidiaries, develops, manufactures, markets, and distributes single-use medical devices used in minimally invasive procedures in the cardiovascular system. Its products are used to cross, prepare, and treat arterial blockages in the legs and heart, and to remove pacemaker and defibrillator cardiac leads. The company's vascular intervention product line includes crossing solutions, which support catheters to facilitate crossing of peripheral and coronary arterial blockages, and retrograde access and guidewire retrieval devices used in the treatment of peripheral arterial blockages, including chronic total occlusions; peripheral atherectomy, a range of laser catheters for ablation of blockages in arteries above and below the knee; and coronary atherectomy and thrombectomy, which are aspiration for the treatment of blockages in the heart. Its primary crossing catheters include Quick-Cross, Quick-Cross Select, and Quick-Cross Extreme; the ELCA Laser Ablation Catheter for coronary atherectomy; and QuickCat aspiration catheter for thrombus management. The company's lead management product line comprises excimer laser sheaths, non-laser mechanical sheaths, and cardiac lead management accessories, such as Spectranetics Laser Sheath, and Lead Locking Device for the removal of pacemaker and defibrillator cardiac leads. It also offers the Stellarex DCB platform that is designed to treat peripheral arterial disease. The company sells its products in the United States, Canada, Europe, the Middle East, the Asia Pacific, Latin America, and Puerto Rico. The Spectranetics Corporation was founded in 1984 and is headquartered in Colorado Springs, Colorado.

753 Employees
Last Reported Date: 02/27/15
Founded in 1984

spectranetics corp (SPNC) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $966.6K
Chief Operating Officer
Total Annual Compensation: $448.5K
Senior Vice President and General Counsel
Total Annual Compensation: $392.0K
Senior Vice President of Sales & Marketing fo...
Total Annual Compensation: $390.0K
Compensation as of Fiscal Year 2014.

spectranetics corp (SPNC) Key Developments

The Spectranetics Corporation Announces FDA Clearance of Turbo-Power Laser Atherectomy Catheter, Only Indicated Atherectomy Device for Treatment of In-Stent Restenosis

The Spectranetics Corporation announced the receipt of U.S. Food and Drug Administration (FDA) 510(k) clearance of its peripheral atherectomy product, the Turbo-Power Laser Atherectomy Catheter, for the treatment of in-stent restenosis (ISR). Laser atherectomy is driving a new standard of care for in-stent restenosis treatment with improved clinical outcomes and products that evolve to meet patient and physician needs. Uniquely designed to optimize ISR treatment, the Turbo-Power™ Laser Atherectomy Catheter treats at the tip with vaporizing technology for maximal luminal gain. The device debulks the lesion in a single step and offers remote automatic rotation for precise directional control. The EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal (arteries above the knee) In-Stent Restenosis (EXCITE ISR) is the first of its kind, large multicenter, prospective randomized trial ever conducted for the treatment of FemPop ISR. Durable results show that Spectranetics' laser atherectomy devices used with PTA (also known as balloon angioplasty) are safer and more effective than PTA alone for treating FemPop ISR based on two key data findings: Primary safety endpoint, major adverse events (MAEs) rates at 30 days 5.4% vs. 20.8% with PTA alone (p<0.001). Primary efficacy endpoint, freedom from target lesion revascularization (TLR) through six months 78.3% vs. 58.9% with PTA alone (p=0.002).

The Spectranetics Corporation Presents at Stifel Healthcare Conference 2015, Nov-18-2015 11:45 AM

The Spectranetics Corporation Presents at Stifel Healthcare Conference 2015, Nov-18-2015 11:45 AM. Venue: The New York Palace Hotel, Hubbard Room, New York, New York, United States. Speakers: Scott William Drake, Chief Executive Officer, President and Director.

The Spectranetics Corporation Presents at Canaccord Genuity 2015 Medical Technology & Diagnostics Forum, Nov-19-2015 11:00 AM

The Spectranetics Corporation Presents at Canaccord Genuity 2015 Medical Technology & Diagnostics Forum, Nov-19-2015 11:00 AM. Venue: Westin Grand Central, New York, New York, United States.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SPNC:US $13.76 USD +0.25

SPNC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AngioDynamics Inc $11.77 USD +0.18
AtriCure Inc $22.41 USD +0.17
Cardiovascular Systems Inc $16.52 USD -0.03
Endologix Inc $10.35 USD +0.11
Vascular Solutions Inc $35.54 USD +0.02
View Industry Companies

Industry Analysis


Industry Average

Valuation SPNC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.4x
Price/Book 4.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.2x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact SPECTRANETICS CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at